 CAMBRIDGE, Mass.--BUSINESS WIRE--Infinity Pharmaceuticals, Inc. NASDAQ: INFI will be presenting data from MARIO-275 on the first day of the American Society of Clinical Oncology ASCO 2021 Genitourinary Cancers Symposium to be held virtually, February 11-13, 2021. MARIO-275 is a randomized, placebo- controlled Phase 2 study evaluating the benefit of adding eganelisib to nivolumab Opdivo in platinum-refractory, IO naïve patients with advanced urothelial cancer over nivolumab monotherapy 